BioSpace

Your source for biopharma news and jobs

[BioSpace @biospace]

Updated Today - BioSpace's IPO dashboard helps the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.

https://t.co/HqSukHk60g

[BioSpace @biospace]

Caribou Biosciences entered the scene in 2011 and went public in 2021. Over the course of its existence, the biotech has received funding and support from a handful of Big Pharma players, including Novartis, AbbVie and Pfizer.

https://t.co/TmDIJf8Kk9

[BioSpace @biospace]

The investment will equip Bayer to make oncology, cardiovascular and renal care ingredients and drugs.

https://t.co/mWObTq8Tr7

[BioSpace @biospace]

Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced and derisked assets, as well as AI-driven drugmakers.

https://t.co/emKmC2niZq

[BioSpace @biospace]

The person you expect to address the company’s problems should know the challenges your business faces. Not having that context will limit what they can accomplish.

https://t.co/EtXr1LU2hH

[BioSpace @biospace]

Genmab and AbbVie’s new Epkinly data wow analysts and could support expanded approval in diffuse large B cell lymphoma; Novartis makes a nearly $8B mRNA bet with China’s Abogen Biosciences; and could Sarepta Therapeutics rebound from last year’s setbacks?

https://t.co/kUDsY7henn

[BioSpace @biospace]

With its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-telangiectasia, according to Jefferies.

https://t.co/1NiYHEZkyx

[BioSpace @biospace]

Despite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.

https://t.co/UkJ5E3ZCM9

[BioSpace @biospace]

AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival used alongside a frontline regimen in diffuse large B cell lymphoma—potentially setting up a battle with Roche’s Polivy.

https://t.co/dv6OX6QTom

[BioSpace @biospace]

Adecto Pharmaceuticals and Aviceda Therapeutics are exiting the biotech scene, although Adecto’s CEO hopes the company’s work can continue.

https://t.co/AVu4kScTJ4

[BioSpace @biospace]

While AI is taking off in biopharma for administrative tasks and drug discovery efforts, more than 90% of drugmakers have yet to commit to scaling AI use in regulated biopharma manufacturing, according to CRB’s new Horizons: Life Sciences report.

https://t.co/fQXNCHCGmk

[BioSpace @biospace]

40 Under 40 honorees’ accomplishments include co-developing the world’s first synthetic biology programming language for mRNA and co-founding and leading a company acquired for $700 million up-front and up to $1.225 billion in total consideration.

https://t.co/91eYBFEI6d

[BioSpace @biospace]

Introducing BioSpace’s 2026 40 Under 40! ✨

This incredible group of leaders is shaping the future of biotech and pharma.

https://t.co/o4PnESwSgw

[BioSpace @biospace]

Adecto Pharmaceuticals has ceased operations, while Aviceda Therapeutics is in the process of winding down.

https://t.co/vY58SooO6a

[BioSpace @biospace]

Eli Lilly first linked up with Gate Bioscience in July 2025 to leverage the biotech’s Molecular Gate engine to treat diseases with high unmet need. Monday’s expansion will add one undisclosed target to the existing agreement, with an option for a second.

https://t.co/QtLKrCQjES

[BioSpace @biospace]

After a series of clinical-stage failures, Alector is resetting around its preclinical blood-brain barrier delivery technology, securing a big pharma partnership along the way.

https://t.co/60FWQ4pK5Z

[BioSpace @biospace]

CSL will co-develop and co-promote Alentis Therapeutics’ anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune disease characterized by small blood vessel inflammation.

https://t.co/j5pbJmKjLz

[BioSpace @biospace]

All signs point forward for Biogen’s initial foray into lupus, as litifilimab elicited clear or almost clear skin in one year in patients with cutaneous lupus in Phase 2. Data from two Phase 3 studies of systemic lupus are expected by the end of the year.

https://t.co/oyA63EHYJg

[BioSpace @biospace]

VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ambitious scenario and setting Vaxcyte up to challenge the Big Pharmas in a market worth $8 billion.

https://t.co/JVH3v8Wj11

[BioSpace @biospace]

Recently laid off from a biopharma company? We would like to hear from you about what goes on behind the scenes. If you’re willing to share your story for possible inclusion in a future article, please visit this link. Thank you!

https://t.co/VOvt5PQxVG